Chinese remedies could bolster Big Pharma pipelines; Pfizer's gold dust debacle;

Conversations on Twitter :

 @FierceBiotech: Eli Lilly hits the brakes on PhIII program in arthritis after 'unexpected' results. Story | Follow @FierceBiotech

@JohnCFierce: Who releases PhIII results one endpoint at a time? Stock up, but $ONCY PR is weak, manipulative. Count me skeptical. More | Follow @JohnCFierce

@RyanFierce: AZN missed big in Phase IIb for oral arthritis drug after previous mixed results. Should have killed program earlier? Report | Follow @RyanMFierce

> GlaxoSmithKline ($GSK), Sanofi ($SNY) and others from the pharma world have turned to traditional Chinese remedies for new potential drugs. Article

> Add another deal to the growing list of tie-ups between pharma outfits and academics. Eisai has struck an R&D alliance with University College London focused on therapies for Alzheimer's and other neurological diseases. Report

> Synta Pharmaceuticals ($SNTA), a developer of drugs against cancer and inflammation, has raised $60 million in a sale of common stock to its board members and institutional investors. Release

> The FDA accepted a New Drug Application for Lundbeck and Takeda's antidepressant. Item

> The contract research outfit Huntingdon Life Sciences could ax up to 100 jobs, blaming weak demand for outsourcing from pharma companies. Report

Pharma News

@FiercePharma: KV says it's set to emerge from bankruptcy. News | Follow @FiercePharma

> Pfizer to pay $55 million to clean Wyeth's dirty laundry. Item

> AstraZeneca, Lilly feeling real pain in race for arthritis drugs. News

> FDA risk finding adds fuel to fire around Pfizer's Chantix. Story

Medical Device News

 @FierceMedDev: AspenBio Pharma seeks rebirth as Venaxis, with focus on diagnostics. More | Follow @FierceMedDev

@MarkHFierce: A conservative Washington Post blogger calls out medical device tax "hypocrites" who voted for it and now oppose it. Story | Follow @MarkHFierce

 @DamianFierce: Between FDA earfuls, analyst warnings and, now, a shareholder lawsuit, St. Jude Medical is having a rough winter. Article | Follow @DamianFierce

> Covidien gets Canadian nod for stroke-treating Solitaire. News

> Biocartis bags $44.5M Series D for molecular Dx commercialization. More

> St. Jude faces shareholder suit over Durata claims. Report

Vaccine News

> GSK employs mobile phones to up vaccination rates in Africa. Report

> TB vaccine tested in infants of HIV-positive mothers. News

> IDRI fetches $10M from Gates Foundation for adjuvant research. Story

> GAVI Alliance aims to immunize 30 million girls against HPV. Item

> Global pediatric vaccine market to hit $23B by 2015. Article

Pharma Manufacturing News

> Court OKs drug-shortage lawsuit against Hospira. News

> Manufacturing at the heart of Teva's $2B cost-cutting drive. Story

> 6 hospitalized as Novartis manufacturing stumbles again. Article

And Finally… Since investigators began a hunt for Pfizer's missing gold dust, industry watchers have been speculating on what the drug giant ($PFE) was doing with all the precious metal in the first place. Blog

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.